TLRs are innate immune receptors that are responsible, directly or indirectly, for detecting pathogen-associated molecular patterns (PAMPs) and responding to them through the activation of innate and adaptive immune pathways.

Molecular Templates has commenced dosing in Phase 1 trial of MT-8421, a unique engineered toxin body targeting CTLA-4, for treating advanced solid tumors.

This article summarized the latest R&D progress of Naftifine Hydrochloride, the Mechanism of Action for Naftifine Hydrochloride, and the drug target R&D trends for Naftifine Hydrochloride.

TTerns Pharmaceuticals reported the initial participant administration in Phase 1 Clinical Testing of TERN-601 Oral GLP-1 Receptor Agonist, a potential treatment for obesity.

Mesenchymal stem cells (MSCs) have broad therapeutic potential for treating inflammation and degenerative diseases.

This article summarized the latest R&D progress of Naloxegol Oxalate, the Mechanism of Action for Naloxegol Oxalate, and the drug target R&D trends for Naloxegol Oxalate.

Endothelin receptor are G protein-coupled receptors (GPCRs) of the β-group of rhodopsin receptors that bind to endothelin ligands, which are 21 amino acid long peptides derived from longer prepro-endothelin precursors.

Clinical-stage biopharmaceutical firm Inhibrx declared initial Phase 1 trial results for INBRX-109, used with Irinotecan and Temozolomide, to treat advanced, non-removable Ewing sarcoma. The trial focused on efficacy and safety.

Motifs in biology refer to nucleotide or amino-acid sequence patterns that are prevalent and usually associated with the biological function of a macromolecule.

This article summarized the latest R&D progress of Nebivolol hydrochloride, the Mechanism of Action for Nebivolol hydrochloride, and the drug target R&D trends for Nebivolol hydrochloride.

Chemical modifications in biology refer to the changes in biomolecular structure and function brought about by the addition or removal of modifying elements.

IDRx, Inc. has reported initial clinical results from its ongoing Phase 1 StrateGIST trial of IDRX-42. This trial is for patients with metastatic and/or inoperable gastrointestinal stromal tumors who have previously received at least one tyrosine kinase inhibitor therapy regime, now testing a higher dosage.